Member Info for daveycaferacer

Unfortunately the SEC have reversed the reversed decision of yesterday and Chinese Telco's will be de-listed in the United States. This has probably caused negative sentiment across all U.S. listed China related stocks today.

apologies, yes, getting the two mixed up ;-/

Because the Prospectus said that Ordinary Shares will cease to be traded on AIM 7.00 a.m. on 21 January 2021 and Admission and commencement of dealings in Ordinary Shares on the main List will commence at 8.00 a.m. on 21 January 2021

correction, 11 days

In theory only 16 working days left until Accustem shares are listed and begin trading

indeed amones, although we are still at the price we were at in Dec 2017 so I hope there is some way to go yet. The Co. is still undervalued in my view.

If CKHH do divest I hope they go about it in a better fashion than they did in Dec 2018 - we have only just fully recovered from that particular activity!

The SEC's decision to ignore the President's Executive order to de-list Chinese Telecoms firms seems to have had a positive impact on all Chinese listed adr's

Hopefully the previous administrations threats against Chinese listed Co's with listings in the U.S. will gradually fade away as it doesn't seem to serve anyone well, including U.S. Investors

Currently the feedback is anecdotal. Dr Weiner stated yesterday that they are waiting the results of blood tests that will measure certain biomarkers. Once this data is collated and published that will contain the real scientific evidence that the medical community will be interested in.

You will not have to sell & re-buy, the transfer will be automatic and given the fact the Ticker will probably remain the same, you will probably see absolutely no difference in your account. That has been my experience previously.

to add, I know I am entitled to Accustem shares so I am not distracted by the nuances of ADR holders and their rights ;o-)

When you instruct your broker to buy ordinary shares on your behalf, your broker will have the option of buying DIs on AIM, or buying Nasdaq listed ADRs. Conversely, when you wish to sell your position, your broker will either sell them on AIM, or otherwise, may sell them on the Nasdaq market. Any necessary conversion of securities would first be effected in the manner described above. In any event, this would be a seamless process for shareholders. Unless they particularly wish to give specific instructions in that regard (in which case they are free to do so) shareholders will not need to be concerned with which market their shares are purchased from or sold into. Brokers will simply buy or sell in the market where there is the most liquidity at that time.

The above is a general explanation

They can - I’ll post the explanation shortly

Great performance but we are still at the same price/mcap we were at in Nov 2017, so still way undervalued IMO

In addition, there is effectively a single order book for shares / ADR's, if you buy shares they may be settled with adr's and if you buy adr's they may be settled with ordinary shares - I can explain more tomorrow if anyone needs an explanation

ilmer57, are you referring to the longstanding AZ-HCM collaboration or specifically with regards to the patent WO2020/053198?

Trinity Delta have published an updated research note:-

https://www.trinitydelta.org/research-notes/china-approval-clears-sulanda-in-epnet/

Valuation upgrade to £6.45/share or $41.94/ADS

In the first 30 mins of trading we have exceeded the average daily volume

I would doubt whether the impact on the Top Line Data will have a lesser effect if the Co. has a main market listing by the release of the data - NASADAQ tends to drive the price now

"Stocktwits have already picked up on this news."

We certainly did